Search
Prolectin-M
go.drugbank.com/drugs/DB16521Investigational[L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Cetrelimab
go.drugbank.com/drugs/DB15421InvestigationalCetrelimab is under investigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD
ALT-2074
go.drugbank.com/drugs/DB05631InvestigationalBXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Piretanide
go.drugbank.com/drugs/DB02925Approvednames Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the
FX06
go.drugbank.com/drugs/DB05685InvestigationalFX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.
Deferitazole
go.drugbank.com/drugs/DB13120InvestigationalIt has been used in trials studying the treatment and basic science of Beta-thalassemia, Hepatic Impairment, Impaired Renal Function, Transfusional Iron Overload, and Iron Overload Due to Repeated Red
Cixutumumab
go.drugbank.com/drugs/DB12250InvestigationalCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. … Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.
AN0128
go.drugbank.com/drugs/DB05054InvestigationalThe rise in antibiotic resistance of P. acnes to standard antibiotics necessitates the development of new treatment agents.
Streptococcus pneumoniae type 2 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10320ApprovedInvestigationalStreptococcus pneumoniae type 2 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 2 of *Streptococcus pneumoniae*.
Streptococcus pneumoniae type 8 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10326ApprovedInvestigationalStreptococcus pneumoniae type 8 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 8 of *Streptococcus pneumoniae*.